News - Pharmaceutical
Creative Destruction And The Pharmaceutical Industry
6 January 2013
The pharmaceutical industry is in the nascent stages of transition. Until now, the companies that develop and market new drugs have relied upon monopoly or near monopoly protection from patents in order to succeed. Companies invest billions in research ...
Click on the link to read the full article at Seeking Alpha (This link will open in a new window)Pharmaceutical manufacturer Exela to expand Lenoir plant
5 January 2013
Exela Pharma Sciences, a pharmaceutical manufacturer, said Thursday it will expand its plant in Lenoir, adding 38 jobs and spending $8.5 million on capital investments over three years. The company is eligible for an $189,000 grant from the One North ...
Click on the link to read the full article at Winston-Salem Journal (This link will open in a new window)National Pharmaceutical Pricing Authority notifies ceiling prices of 33 drugs
4 January 2013
The National Pharmaceutical Pricing Authority (NPPA) has notified the ceiling prices of 33 drugs as per the new pharmaceutical pricing policy. The notification, NPPA officials say, will have only marginal impact on the prices of most of the drugs ?1-2 ...
Click on the link to read the full article at Indian Express (This link will open in a new window)Paratek Pharmaceutical's 'omadacycline' gets QIDP designation from the FDA
3 January 2013
The Global Dispatch logo Boston, MA company, Paratek Pharmaceuticals, Inc announced today that their lead product candidate, omadacycline received the Food and Drug Administration's (FDA) Qualified Infectious Disease Product (QIDP) designation for ...
Click on the link to read the full article at The Global Dispatch (This link will open in a new window)Pharmaceutical manufacturer to create new jobs in Caldwell County
3 January 2013
Exela, which develops and manufactures injectable and ophthalmic pharmaceutical products, currently employs more than 40 at its Lenoir facility. Salaries will vary by job function, but the average annual wages for the new jobs will be $47,395, plus ...
Click on the link to read the full article at WSOC Charlotte (This link will open in a new window)Bayer HealthCare completes acquisition of Teva Pharmaceutical Industries' U.S. ...
3 January 2013
3, 2013 /PRNewswire/ -- Bayer HealthCare LLC announced today that it has received the necessary regulatory approvals to complete the acquisition of the U.S.-based animal health business of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). Bayer will ...
Click on the link to read the full article at PR Newswire (press release) (This link will open in a new window)175 jobs to be created as pharmaceutical firm Abbott separates its research ...
3 January 2013
The giant pharmaceutical company Abbott has hived off its research division into a new business called AbbVie, which will employ 400 people in Ireland with a further 175 jobs to be created by 2015. AbbVie is listed on the New York Stock Exchange and ...
Click on the link to read the full article at Irish Examiner (This link will open in a new window)Taxpayer-Backed Pharmaceutical Company Fined for Illegal Kickbacks
2 January 2013
A California pharmaceutical company that has received federal subsidies under the Obama Administration agreed to pay $11.4 million last week to settle allegations that it bribed medical professionals to prescribe and sell its drugs. The allegation was ...
Click on the link to read the full article at Heritage.org (blog) (This link will open in a new window)NOVARTIS CEO: Big Pharma Has To Move Beyond Just 'Selling The Pill'
2 January 2013
Though universities and hospitals may make initial discoveries, it's only pharmaceutical companies that are able to complete the incredibly complex, costly, and time consuming process of bringing a drug to market. Related: Why It's A Miracle That Any ...
Click on the link to read the full article at Business Insider (This link will open in a new window)2013 Pharmaceutical Industry Outlook: Post-Election Impact to Healthcare ...
2 January 2013
The 2012 election was filled with tight races, close victories and upsets. Now that the votes are in, and the Obama Administration begins a second term in office, questions remain about the continued implementation of the Patient Protection and ...
Click on the link to read the full article at Pharmaceutical Processing (This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
